Home > News
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers


COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with cancer.

FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation


Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial


FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion


FGFR2 fusions appear to be much less frequent in tumours arising in the context of chronic liver fluke infection, the most common aetiology in SE Asia.


Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update(2)


Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update


Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers


Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]


Oncodna logo - wideToggle main menu visibility ENDOMETRIAL CANCER: Data from SGO 2020 indicate survival benefit for the addition of trastuzumab to standard chemo for those with advanced ERBB2-expressing (HER2+) disease (OS 24.4 versus 29.6 months) April 27, 2020 SCIENTIFIC Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002): Updated survival analysis


Findings from three clinical trial arms of precision medicine released at 2018 (at ASCO meeting in Chicago) on the study developed by NCI and ECOG-ACRIN:
: NCI-MATCH, a phase 2 clinical trial, seeks to determine whether targeted therapies for people whose tumors have certain gene mutations will be effective regardless of their cancer type, using ...